CN104721164B - A kind of cinacalcet hydrochloride Film coated tablets composition - Google Patents
A kind of cinacalcet hydrochloride Film coated tablets composition Download PDFInfo
- Publication number
- CN104721164B CN104721164B CN201510132899.7A CN201510132899A CN104721164B CN 104721164 B CN104721164 B CN 104721164B CN 201510132899 A CN201510132899 A CN 201510132899A CN 104721164 B CN104721164 B CN 104721164B
- Authority
- CN
- China
- Prior art keywords
- cinacalcet hydrochloride
- film
- coated tablets
- film coated
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000478 cinacalcet hydrochloride Drugs 0.000 title claims abstract description 47
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 title claims abstract description 47
- 239000007941 film coated tablet Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000007888 film coating Substances 0.000 claims abstract description 34
- 238000009501 film coating Methods 0.000 claims abstract description 34
- 238000004090 dissolution Methods 0.000 claims abstract description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960000540 polacrilin potassium Drugs 0.000 claims abstract description 12
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 11
- 239000010410 layer Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- 210000002784 stomach Anatomy 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 abstract description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000012467 final product Substances 0.000 description 6
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960003315 cinacalcet Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical compound CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- -1 3- (trifluoromethyl) phenyl Chemical group 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229960002919 dronedarone hydrochloride Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 201000003913 parathyroid carcinoma Diseases 0.000 description 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 229940116949 sensipar Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of cinacalcet hydrochloride Film coated tablets composition and preparation method thereof.Cinacalcet hydrochloride Film coated tablets of the invention contains cinacalcet hydrochloride, polacrilin potassium, microcrystalline cellulose, silica, magnesium stearate and film-coating, has the advantages that simple formulation and technology, low cost, dissolution are good.
Description
Technical field
The present invention relates to technical field of medicine, and in particular to a kind of cinacalcet hydrochloride Film coated tablets composition.
Background technology
Cinacalcet hydrochloride (Cinacalcet Hydrochlorid) chemical name N- ((1R) -1- (1- naphthyls) ethyl) -3-
(3- (trifluoromethyl) phenyl) propyl- 1- amine hydrochlorates, molecular formula C22H22F3NHCl, structural formula is as follows：
Hyperparathyroidism causes parathormone (PTH) to raise, and alcium and phosphor metabolization changes, and may induce sclerotin and dredge
The illnesss such as pine, coronary heart disease.Calcium level is raised can cause the disease such as amentia, drowsiness, dehydration, nausea, constipation.Hydrochloric acid Xi Naka
Plug is a kind of Sensipar, can reduce internal parathormone (PTH) and serum calcium level, adjusts alcium and phosphor metabolization, treatment treatment
The hypercalcinemia that parathyroid carcinoma causes.
Dissolving of the cinacalcet hydrochloride in water depends on pH, almost insoluble in the water of neutral pH, in the artificial of pH6.8
Dissolution is very low in intestinal juice.Cinacalcet hydrochloride is main in intestinal absorption, and the dissolution in enteron aisle is the premise that it is absorbed.
Patent application CN102198108A, CN102885792A etc. in the prior art, using micronizing, or are made solid composite, or
Using dry granulation etc., existing needs the defects such as Special Equipment, preparation time are long, cost is high.
Therefore, developing a kind of process is simple, with low cost, dissolution rate cinacalcet hydrochloride solid pharmaceutical preparation product high turns into
The active demand of those skilled in the art.
The content of the invention
It is an object of the invention to provide a kind of preparation process is simple, with low cost, dissolution rate cinacalcet hydrochloride piece high
Agent product.By numerous studies for many years, it has been found that a kind of to be particularly well-suited to the auxiliary of cinacalcet hydrochloride solid pharmaceutical preparation
Material --- polacrilin potassium.Cinacalcet hydrochloride Film coated tablets is prepared using polacrilin potassium and silica, can not only be improved
The dissolution of cinacalcet hydrochloride, and dissolution in 15 minutes can reach more than 85% in the medium of different pH, and can be straight
Compressing tablet is connect, prescription and technique is simplified, cost is saved, the present invention is completed accordingly.
Particularly, when the weight ratio of cinacalcet hydrochloride, polacrilin potassium and silica is 5：1：When 2, present invention system
The dissolving out capability of standby cinacalcet hydrochloride Film coated tablets is particularly pertinent.If cinacalcet hydrochloride, polacrilin potassium and dioxy
The weight ratio of SiClx is higher or lower than 5：1：2, the dissolution of the cinacalcet hydrochloride Film coated tablets prepared by same process
Performance is then substantially reduced.
Specifically, the invention provides a kind of cinacalcet hydrochloride Film coated tablets composition, by piece sandwich layer and film-coating layer
Composition, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
0.8-1.2：10.
As optimal technical scheme, wherein the weight ratio of the cinacalcet hydrochloride, polacrilin potassium and silica is
5：1：2.
Specifically, the invention provides following cinacalcet hydrochloride Film coated tablets：
(1) a kind of cinacalcet hydrochloride Film coated tablets, is made up of piece sandwich layer and film-coating layer, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 1：
10。
(2) a kind of cinacalcet hydrochloride Film coated tablets, is made up of piece sandwich layer and film-coating layer, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
0.8：10.
(3) a kind of cinacalcet hydrochloride Film coated tablets, is made up of piece sandwich layer and film-coating layer, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
1.2：10.
Invention can prepare piece sandwich layer using the method for direct tablet compressing, then through conventional coating procedure, you can this hair is obtained
Bright cinacalcet hydrochloride Film coated tablets.
The cinacalcet hydrochloride Film coated tablets that the present invention is originally made of auxiliary materials such as polacrilin potassium, silica
The dissolving of cinacalcet hydrochloride can be increased in enteron aisle, dissolution of the cinacalcet hydrochloride in intestinal juice is substantially increased.Especially need
It is noted that when the weight ratio of cinacalcet hydrochloride, polacrilin potassium and silica is 5：1：When 2, prepared by the present invention
The dissolving out capability of cinacalcet hydrochloride Film coated tablets is substantially better than above-mentioned weight than other different technical schemes.As a result of
Above-mentioned technical proposal, the present invention achieves following beneficial effect：Dissolution rate is high, low cost, preparation process is simple, is adapted to industry
Metaplasia is produced.It is further preferred that based on the design of scientific and rational prescription, cinacalcet hydrochloride Film coated tablets of the invention
Prepared by directly compressible method, greatly save production cost, simplifies production technology, and industrialization prospect is very wide.
Specific embodiment
Specific embodiment of the invention is only further to carry out illustrative explanation to the present invention, is not necessarily to be construed as to this
Any limitation of invention.
Raw and auxiliary material used is purchased in market in embodiment.
The cinacalcet hydrochloride Film coated tablets of the invention of embodiment 1
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 1：
10。
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (25mg/ pieces).
The cinacalcet hydrochloride Film coated tablets of the invention of embodiment 2
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
0.8：10.
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (75mg/ pieces).
The cinacalcet hydrochloride Film coated tablets of the invention of embodiment 3
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
1.2：10.
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (25mg/ pieces).
Embodiment 4 cinacalcet hydrochloride Film coated tablets (cinacalcet hydrochloride, polacrilin potassium and silica of the invention
Weight ratio be 5：1：2)
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 1：
10。
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (25mg/ pieces).
Embodiment 5 cinacalcet hydrochloride Film coated tablets (cinacalcet hydrochloride, polacrilin potassium and silica of the invention
Weight ratio be 5：1：2)
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
1.1：10.
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (25mg/ pieces).
Embodiment 6 cinacalcet hydrochloride Film coated tablets (cinacalcet hydrochloride, polacrilin potassium and silica of the invention
Weight ratio be 5：1：2)
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio is
0.9：10.
Preparation technology：
Take supplementary material to be well mixed, compressing tablet is coated, and obtains final product (75mg/ pieces).
The dissolution study of experimental example dronedarone hydrochloride piece
Cinacalcet hydrochloride Film coated tablets, presses obtained in Example 1~6《Chinese Pharmacopoeia》The two annex XC of version in 2010
Second method determines dissolution rate.Leaching condition：Respectively with 0.1mol/L hydrochloric acid solutions, pH4.5 phosphate buffers, pH6.8 phosphoric acid
Salt buffer is dissolution medium, and volume 900ml, 50 turns/min of rotating speed are operated in accordance with the law, during through 15 minutes, take solution 10ml, filter
Cross, discard just filtrate 3ml, precision measures subsequent filtrate 5.0ml, put in 10ml measuring bottles, with flowing phase dilution and being settled to scale, shake
It is even, as need testing solution；It is filler (150mm*4.6mm) with octadecylsilane chemically bonded silica；With containing 0.5% triethylamine
30mmol/L potassium dihydrogen phosphate aqueous solutions (phosphoric acid adjust pH be 2.5)：Acetonitrile=60:40 is mobile phase；Flow velocity is 1.3mL/
Min, Detection wavelength is 220nm, 40 DEG C of column temperature.Precision measures the μ l of need testing solution 10, injects liquid chromatograph, records chromatogram
Figure；Contain cinacalcet about during it is appropriate that another precision weighs cinacalcet hydrochloride reference substance, plus flowing phased soln and diluting is made every 1ml
It is 15 μ g (25mg specifications) and the solution of 40 μ g (75mg specifications), as reference substance solution, is measured in the same method.By external standard method with peak face
Product calculates the stripping quantity of every, as a result as follows：
| 0.1mol/L hydrochloric acid solutions | PH4.5 phosphate buffers | PH6.8 phosphate buffers | |
| Embodiment 1 | 98.1% | 92.0% | 77.3% |
| Embodiment 2 | 99.5% | 95.4% | 75.6% |
| Embodiment 3 | 98.7% | 92.8% | 72.3% |
| Embodiment 4 | 99.9% | 99.2% | 98.9% |
| Embodiment 5 | 100.0% | 99.4% | 98.4% |
| Embodiment 6 | 99.2% | 99.7% | 98.5% |
| Commercialized product | 99.5% | 88.1% | 25.0% |
Claims (4)
1. a kind of cinacalcet hydrochloride Film coated tablets, is made up of piece sandwich layer and film-coating layer, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 0.8-
1.2：10；
Wherein, the cinacalcet hydrochloride and the weight ratio of polacrilin potassium, silica are 5：1：2.
2. cinacalcet hydrochloride Film coated tablets according to claim 1, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 1：10.
3. cinacalcet hydrochloride Film coated tablets according to claim 1, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 0.8：
10。
4. cinacalcet hydrochloride Film coated tablets according to claim 1, wherein,
Piece sandwich layer：
Wherein, the prescription composition of film-coating layer is：Opadry stomach dissolution type film-coating pre-mixing agent and purified water, weight ratio are 1.2：
10。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510132899.7A CN104721164B (en) | 2015-03-25 | 2015-03-25 | A kind of cinacalcet hydrochloride Film coated tablets composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510132899.7A CN104721164B (en) | 2015-03-25 | 2015-03-25 | A kind of cinacalcet hydrochloride Film coated tablets composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104721164A CN104721164A (en) | 2015-06-24 |
| CN104721164B true CN104721164B (en) | 2017-07-07 |
Family
ID=53445966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510132899.7A Active CN104721164B (en) | 2015-03-25 | 2015-03-25 | A kind of cinacalcet hydrochloride Film coated tablets composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721164B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213346B (en) * | 2015-11-02 | 2019-03-26 | 北京泰德制药股份有限公司 | A kind of pharmaceutical composition and preparation method thereof containing cinacalcet hydrochloride |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946382A (en) * | 2003-09-12 | 2007-04-11 | 安姆根有限公司 | Rapid dissolution formulation of a calcium receptor-active compound |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| CN102552258A (en) * | 2012-02-24 | 2012-07-11 | 北京协和药厂 | Pharmaceutical composition containing repaglinide and preparation method of same |
| CN103933005A (en) * | 2014-05-15 | 2014-07-23 | 严白双 | Pantoprazole sodium-containing enteric-coated tablet and preparation method thereof |
| WO2014207691A1 (en) * | 2013-06-26 | 2014-12-31 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
-
2015
- 2015-03-25 CN CN201510132899.7A patent/CN104721164B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946382A (en) * | 2003-09-12 | 2007-04-11 | 安姆根有限公司 | Rapid dissolution formulation of a calcium receptor-active compound |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| CN102552258A (en) * | 2012-02-24 | 2012-07-11 | 北京协和药厂 | Pharmaceutical composition containing repaglinide and preparation method of same |
| WO2014207691A1 (en) * | 2013-06-26 | 2014-12-31 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
| CN103933005A (en) * | 2014-05-15 | 2014-07-23 | 严白双 | Pantoprazole sodium-containing enteric-coated tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104721164A (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861106B (en) | Preparation method of compound paracetamol and amantadine pellets | |
| CN104382875B (en) | A kind of pantoprazole sodium enteric tablet and preparation method thereof | |
| CN103127025B (en) | The preparation method of racemization 2-(Alpha-hydroxy amyl group) benzoate sheet | |
| CN105004693A (en) | Tablets containing Apremilast active ingredients and vitro dissolution determination method thereof | |
| CN103099790B (en) | A kind of tablet containing everolimus and preparation method thereof | |
| CN105213346A (en) | A kind of pharmaceutical composition containing cinacalcet hydrochloride and preparation method thereof | |
| CN104721164B (en) | A kind of cinacalcet hydrochloride Film coated tablets composition | |
| CN103585122A (en) | Tablet containing everolimus, and preparation method thereof | |
| CN106176653A (en) | A kind of pharmaceutical composition of sitagliptin | |
| CN104473892B (en) | It is a kind of for faropenem composition of sodium of direct tablet compressing and preparation method thereof | |
| CN104997744B (en) | A kind of high stability capecitabine tablet and preparation method thereof | |
| CN104188927B (en) | A kind of Mosapride Citrate Tablets agent and preparation method thereof | |
| CN103933005B (en) | A kind of enteric coatel tablets containing Pantoprazole Sodium and preparation method thereof | |
| CN106798750B (en) | A kind of preparation method of compound omeprazole dry suspension | |
| CN105232503B (en) | A kind of dapoxetine hydrochloride piece | |
| CN104622826A (en) | Mosapride citrate tablet and preparation method thereof | |
| CN104825449A (en) | Compound composition containing atorvastatin calcium and amlodipine and preparation method of same | |
| CN104434852B (en) | Famciclovir vertical compression piece and preparation method thereof | |
| CN104840427A (en) | Pharmaceutical composition containing montelukast sodium | |
| CN105596311A (en) | Riociguat oral solid preparation and preparing method thereof | |
| CN110907583B (en) | Method for separating related substances in loxoprofen or sodium salt thereof | |
| CN104856970A (en) | Vildagliptin tablet for treating type 2 diabetes mellitus | |
| CN103385862B (en) | A kind of metoprolol tartrate extended release tablets and preparation method thereof | |
| CN102772390B (en) | Venlafaxine hydrochloride sustained release capsule and preparation method thereof | |
| CN104398482A (en) | Indapamide slow release medicine containing composite lactose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 051500 Haixing Road, Zhaoxian County Industrial Park, Shijiazhuang, Hebei Patentee after: HEBEI RENHE YIKANG PHARMACEUTICAL Co.,Ltd. Address before: 053411 Hengshui City, Hebei, Wuyi County, Qing Liang store town Patentee before: HEBEI RENHE YIKANG PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211129 Address after: 050000 2 / F, Hongchang science and Technology Park, 238 Changjiang Avenue, high tech Zone, Shijiazhuang City, Hebei Province Patentee after: Renhe Yikang Group Co.,Ltd. Address before: 051500 Haixing Road, Zhaoxian County Industrial Park, Shijiazhuang, Hebei Patentee before: HEBEI RENHE YIKANG PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 051530 No. 7, Haixing Road, industrial park, xinzhaidian Town, Zhao county, Shijiazhuang City, Hebei Province Patentee after: Renhe Yikang Group Co.,Ltd. Address before: 050000 2 / F, Hongchang science and Technology Park, 238 Changjiang Avenue, high tech Zone, Shijiazhuang City, Hebei Province Patentee before: Renhe Yikang Group Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A combination of cinacalcet hydrochloride film coated tablets Granted publication date: 20170707 Pledgee: Cangzhou Bank Co.,Ltd. Xinji sub branch Pledgor: Renhe Yikang Group Co.,Ltd. Registration number: Y2024980034736 |